Company Overview
About OpenBiome
OpenBiome is a Cambridge, Massachusetts-based nonprofit health research organization — backed by Y Combinator (W20) — that operated as the largest distributor of fecal microbiota transplant (FMT) products in the United States for over a decade, providing investigational FMT therapy to thousands of patients with recurrent Clostridioides difficile (C. diff) infection while accelerating research on human microbiome therapeutics. Founded in 2012, OpenBiome suspended FMT distribution as of December 31, 2024, following FDA regulatory changes that ended enforcement discretion for investigational FMT, and submitted an IND Phase 2 protocol application in November 2024 to pursue the FDA-approved clinical pathway for continued microbiome therapeutic development.
Business Model & Competitive Advantage
OpenBiome's FMT distribution model addressed the critical gap between proven clinical efficacy and patient access for one of medicine's most evidence-backed interventions: C. diff infection affects 500,000 Americans annually with 30,000+ deaths, and recurrent C. diff (failing 2+ antibiotic courses) responds to FMT at 80-90% cure rates versus 30-40% for additional antibiotics — but FMT requires a screened, tested donor stool sample that most hospital systems cannot safely source independently. OpenBiome's centralized manufacturing model (rigorous donor screening for pathogens, standardized processing for safety and efficacy, distribution to 1,000+ hospitals and outpatient centers) enabled physicians nationwide to offer FMT under FDA enforcement discretion while building the clinical evidence base that informed the FDA's eventual approval pathway. The decade of distribution data and outcomes collection made OpenBiome the world's largest clinical FMT dataset.
Competitive Landscape 2025–2026
In 2025, OpenBiome navigates the post-enforcement-discretion regulatory transition alongside commercial microbiome therapeutic companies Seres Therapeutics (NASDAQ: MCRB, VOWST approved for C. diff, FDA-approved FMT-derived therapy) and Ferring Pharmaceuticals (REBYOTA, FDA-approved live biotherapeutic for C. diff). The FDA's transition from enforcement discretion to formal drug approval pathways for FMT-derived products (driven by safety concerns about serious adverse events in immunocompromised patients) has reorganized the FMT landscape around IND-approved clinical trials and commercial biologics. OpenBiome's IND Phase 2 submission positions the nonprofit to continue contributing to microbiome research within the formal regulatory framework. The 2025 strategy focuses on completing the Phase 2 clinical trial for the IND-approved FMT program, building the research partnerships with academic medical centers for microbiome science advancement, and advocating for patient access pathways during the transition from investigational FMT to commercially approved microbiome therapeutics.
Recent Activity
View all →Quarterly Report filed 2026-05-07
Material Event filed 2026-05-07
Proxy Statement filed 2026-04-28
Today, the OpenBiome Foundation announced the unanimous election of its Board Leadership for a three-year term, effective immediately. The officers, representing a cross section of innovators – from the clinical, patient, technology and financial fields – will guide the Foundation in its mission to expand patient access to microbiome therapies and drive scientific discoveries that […]
OpenDialog March 2026 – Issue One Patient outcomes may depend on science that’s moving faster than any of us can track. OpenBiome Foundation’s monthly newsletter cuts through the noise – delivering focused conversations with leading researchers and clinicians on the microbiome discoveries most relevant to your practice. The first edition features Dr. L. Clifford McDonald, […]
STAT Feature Article: By Eric Boodman March 23, 2026
Key Differentiators
Emerging Innovator
OpenBiome is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare OpenBiome with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from OpenBiome? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim OpenBiome Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention OpenBiome vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →